Application of matrix-bound nanovesicles derived from adipose-derived mesenchymal stem cells in the preparation of drugs for corneal epithelial injury repair.
By preparing matrix-bound nanovesicles derived from adipose-derived mesenchymal stem cells, the problem of limited drug delivery methods for corneal epithelial damage repair has been solved, achieving non-invasive drug delivery and effective corneal epithelial repair with high safety.
Patent Information
- Application Number
- CN202611502042.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2026-09-24
- Publication Date
- 2026-11-10
AI Technical Summary
In the existing technology, the drug delivery method for corneal epithelial injury repair is limited by surgical operation. Acellular stromal membranes derived from adipose-derived mesenchymal stem cells and nanovesicles obtained by cell disruption differ in origin and composition, and their functional molecules and mechanisms of action in corneal epithelial injury repair are not clearly defined.
Adenocellular extracellular matrix is formed by culturing adipose-derived mesenchymal stem cells. The matrix-bound nanovesicles carrying epidermal growth factor receptors are obtained through enzymatic decomposition and centrifugation and then prepared as eye drops for corneal epithelial damage repair.
It achieves non-invasive local drug delivery, promotes corneal epithelial cell proliferation, reduces the defect area, restores transparency and structure, has high safety, and good batch reproducibility.
Smart Images

Figure CN123059083A_ABST
Abstract
Description
Technical Field
[0001] This invention belongs to the field of biomedical technology, specifically relating to the application of matrix-bound nanovesicles derived from adipose-derived mesenchymal stem cells in the preparation of drugs for the repair of corneal epithelial damage. Background Technology
[0002] The cornea is the outermost transparent tissue of the eyeball, serving as the refractive medium and surface barrier structure, playing a vital role in maintaining visual function and protecting intraocular tissues. The cornea is constantly exposed to the external environment, making it susceptible to mechanical damage, chemical burns, and thermal damage, leading to corneal epithelial cell damage, defects, and even persistent corneal epithelial defects. If this damage is not repaired promptly, it can further cause complications such as corneal infection, stromal ulceration, corneal perforation, and scar formation, resulting in decreased vision or even blindness. Therefore, promoting corneal epithelial repair and restoring corneal transparency is one of the goals in the treatment of ocular surface injuries.
[0003] Decellularized extracellular matrix (dECM) is a biomaterial obtained by removing cellular components while retaining the extracellular matrix structure and related active ingredients. Decellularized extracellular matrix derived from mesenchymal stem cells (MSC-dECM) is biocompatible and retains some of the tissue repair-related components secreted by mesenchymal stem cells.
[0004] Extracellular vesicles (EVs) are nanoscale vesicles with a lipid bilayer structure released by cells. They can carry components such as proteins, nucleic acids, and lipids and participate in intercellular communication, tissue repair, and immune regulation.
[0005] Matrix-bound nanovesicles (MBVs) are a subtype of extracellular vesicles that exist within and bind to the extracellular matrix (ECM). MBVs can carry functional proteins and other bioactive molecules associated with their source cells or tissues, and are considered a class of cell-free therapeutic materials with tissue repair potential.
[0006] Several existing technical solutions related to the aforementioned object already exist, as follows: CN113425909A discloses a decellularized matrix (DMA) material derived from adipose-derived mesenchymal stem cells (ADSCs) and its application in corneal injury repair. This method involves culturing ADSCs to generate extracellular matrix, followed by decellularization to obtain a DMA sheet. This sheet retains various active components from the extracellular matrix, promoting corneal epithelial cell growth and reducing inflammation. However, this method utilizes a complete decellularized matrix sheet, requiring surgical implantation or application to the ocular surface to exert its repair effect, thus limiting the delivery method due to surgical limitations.
[0007] CN118178472A discloses a mesenchymal stem cell-derived nanovesicle eye drop and its application in the treatment of ophthalmic diseases. This method uses mesenchymal stem cells as the source, obtaining cell-derived intracellular nanovesicles (sIVs) through ultrasonic disruption of cells, and then preparing them as eye drops. However, the obtained nanovesicles are derived from cell disruption products, and differ from naturally occurring MBVs in terms of vesicle formation process, molecular composition, and bioactive components. Furthermore, the composition of these cell-disrupted nanovesicles is affected by factors such as cell state and culture conditions, making their origin and composition unclear.
[0008] CN110582286B discloses an ophthalmic application technology based on extracellular matrix molecules (MBVs), involving the isolation and acquisition of MBVs from decellularized extracellular matrix and their application in the treatment of ophthalmic diseases. This scheme primarily utilizes MBVs as a universal bioactive component derived from decellularized matrix, with the MBVs mainly sourced from tissue-derived decellularized extracellular matrix. No research is conducted on MBVs from adipose-derived mesenchymal stem cell-derived decellularized extracellular matrix (ADSC-dECM). The disclosed ophthalmic application involves increasing the survival of retinal ganglion cells, but does not address corneal epithelial damage repair, nor does it reveal the mechanism by which MBVs regulate corneal epithelial regeneration signaling through functional membrane protein delivery.
[0009] In summary, the existing technology has at least the following problems: First, DMA sheets are in sheet form and need to be surgically transplanted to the ocular surface, limiting the drug delivery method due to surgical procedures; second, intracellular nanovesicles (sIVs) obtained through cell disruption differ from MBVs derived from natural extracellular matrix in terms of origin and molecular composition, and their functional composition is unclear; third, current ophthalmic applications of MBVs are mainly based on tissue-derived decellularized matrix, and the compositional characteristics of MBVs in adipose-derived mesenchymal stem cell-derived decellularized extracellular matrix and their application in corneal epithelial injury repair are not clearly defined, nor are the functional molecules that play a role and their mechanisms of regulating corneal epithelial cell repair clearly defined. Summary of the Invention
[0010] To address the problems existing in the prior art, the present invention aims to provide the application of matrix-bound nanovesicles derived from adipose-derived mesenchymal stem cells in the preparation of drugs for the repair of corneal epithelial damage.
[0011] The first aspect of the present invention provides the application of matrix-bound nanovesicles derived from adipose-derived mesenchymal stem cells in the preparation of a drug for the repair of corneal epithelial damage. The matrix-bound nanovesicles are derived from the decellularized extracellular matrix formed by the in vitro culture and deposition of adipose-derived mesenchymal stem cells and obtained by decellularization treatment. The matrix-bound nanovesicles are obtained by enzymatic release and centrifugation separation, and the surface of the matrix-bound nanovesicles carries epidermal growth factor receptors.
[0012] In one embodiment of the present invention, the matrix-bound nanovesicles are prepared by the following steps: (1) Culture adipose-derived mesenchymal stem cells to secrete and deposit them to form extracellular matrix; (2) The extracellular matrix obtained in step (1) is decellularized to obtain adipose-derived extracellular matrix from adipose-derived mesenchymal stem cells; (3) The decellularized extracellular matrix obtained in step (2) is subjected to enzymatic hydrolysis to release matrix-bound nanovesicles, which are then collected by differential centrifugation and ultra-high speed centrifugation to obtain the matrix-bound nanovesicles derived from adipose-derived mesenchymal stem cells.
[0013] In one embodiment of the present invention, the epidermal growth factor receptor carried by the matrix-bound nanovesicles can be transferred and localized to the limbal epithelial cell membrane, and activate the PI3K / AKT signaling pathway and the MAPK / ERK signaling pathway of the limbal epithelial cells.
[0014] In one embodiment of the present invention, the corneal epithelial damage is corneal epithelial damage caused by corneal alkali burn.
[0015] In one embodiment of the present invention, the drug is an eye drop preparation, wherein the concentration of matrix-bound nanovesicles in the eye drop preparation is 1×10⁻⁶.11 ~5×10 11 particles / mL.
[0016] In one embodiment of the present invention, the concentration of matrix-bound nanovesicles in the eye drop formulation is 2.5 × 10⁻⁶ particles. 11 particles / mL.
[0017] In one embodiment of the present invention, the adipose mesenchymal stem cells in step (1) are derived from adipose tissue obtained by liposuction or double eyelid surgery, and the culture medium used for the extracellular matrix deposition culture includes α-MEM medium, exosome-free fetal bovine serum, and penicillin / streptomycin.
[0018] In one embodiment of the present invention, in step (1), fourth-generation adipose-derived mesenchymal stem cells are used for extracellular matrix deposition culture, and the deposition culture time is 14 days.
[0019] In one embodiment of the present invention, the decellularization treatment in step (2) is to treat with 0.5% Triton X-100 and 20 mM ammonium hydroxide for 5 min, followed by washing with Hanks balanced salt solution and ultrapure water in sequence.
[0020] In one embodiment of the present invention, the enzymatic hydrolysis in step (3) is performed by digestion with Liberase TL, wherein the concentration of Liberase TL is 0.01 mg / mL, the digestion solution includes 50 mM Tris buffer, 5 mM CaCl2 and 150 mM NaCl, the pH of the buffer is 7.8, and the digestion is carried out at 37°C for 1 h.
[0021] In one embodiment of the present invention, the differential centrifugation in step (3) is performed sequentially as follows: centrifugation at 500×g for 10 min, centrifugation at 2000×g for 10 min, and centrifugation at 10000×g for 30 min. The supernatant is collected and filtered through a 0.22 μm filter membrane. The ultra-high speed centrifugation is performed as follows: centrifugation at 100000×g and 4℃ for 90 min.
[0022] In one embodiment of the present invention, the matrix binds nanovesicles to express CD9 and TSG101, but not HSPA13.
[0023] A second aspect of the present invention provides a pharmaceutical composition for the repair of corneal epithelial damage, the pharmaceutical composition comprising matrix-bound nanovesicles derived from adipose-derived mesenchymal stem cells and an ophthalmologically acceptable carrier, wherein the matrix-bound nanovesicles derived from adipose-derived mesenchymal stem cells are derived from decellularized extracellular matrix formed by in vitro culture and deposition of adipose-derived mesenchymal stem cells and obtained by decellularization, enzymatic release and centrifugation, and the surface of the matrix-bound nanovesicles carries epidermal growth factor receptors.
[0024] In one embodiment of the present invention, the pharmaceutical composition is an ophthalmic preparation.
[0025] In one embodiment of the present invention, the ophthalmic preparation is an eye drop preparation, an ophthalmic gel, or an ophthalmic sustained-release preparation.
[0026] Compared with the prior art, the beneficial effects of the present invention are as follows: 1. The matrix-bound nanovesicles derived from adipose-derived mesenchymal stem cells provided by this invention are derived from the decellularized extracellular matrix formed by the in vitro culture and deposition of adipose-derived mesenchymal stem cells and subjected to decellularization treatment, obtained through enzymatic desorption and centrifugation. These matrix-bound nanovesicles are administered topically to the ocular surface in nanovesicle form, eliminating the need for surgical implantation or covering of the ocular surface as with DMA sheets, thus changing the current method of administration for adipose-derived mesenchymal stem cell-derived decellularized matrix materials that relies on surgical transplantation.
[0027] 2. The matrix-bound nanovesicles of this invention are derived from the extracellular matrix microenvironment of decellularized adipose-derived mesenchymal stem cells. Their enzymatic release differs from methods that obtain intracellular nanovesicles by ultrasonic cell disruption or by directly isolating extracellular vesicles from culture supernatant in conditioned medium. This process preserves the functional molecules stored in the decellularized extracellular matrix, ensuring a clear origin. The matrix-bound nanovesicles exhibit the protein characteristics of extracellular vesicles (expressing CD9 and TSG101, but not HSPA13) and are enriched with epidermal growth factor receptor (EGFR) on their surface.
[0028] 3. This invention identifies EGFR enriched on the surface of matrix-bound nanovesicles derived from adipose-derived mesenchymal stem cells as a functional molecule promoting corneal epithelial repair. The EGFR carried on the surface of these matrix-bound nanovesicles can transfer and localize to the limbal epithelial cell membrane, activating the PI3K / AKT and MAPK / ERK signaling pathways in limbal epithelial cells, thereby enhancing their proliferative capacity. After blocking EGFR on the surface of these matrix-bound nanovesicles with an EGFR neutralizing antibody, the activation of these signaling pathways and their promoting effect on corneal epithelial cell proliferation were weakened, while treatment with an isotype control antibody did not affect the aforementioned proliferative effect. Simultaneously, matrix-bound nanovesicle treatment did not upregulate the mRNA level of EGFR in limbal epithelial cells themselves, indicating that EGFR is the functional molecule responsible for these effects.
[0029] 4. The matrix-combined nanovesicle eye drop formulation provided by this invention can reduce the area of corneal epithelial defects, restore corneal transparency, reduce corneal edema, restore the multilayer structure of corneal epithelium, and improve the arrangement of corneal stromal collagen fibers. Its effect in promoting the repair of corneal epithelial defects is not inferior to that of the positive control drugs Bepanthen eye drops and DMA films. After long-term ocular surface administration, no obvious abnormalities were observed in the corneal tissue structure and major organs such as the heart, liver, spleen, lungs, and kidneys.
[0030] 5. The method for preparing matrix-bound nanovesicles described in this invention has good batch reproducibility. The particle yield and particle size distribution obtained by normalizing the decellularized extracellular matrix per unit mass of different independent batches are relatively consistent, and the matrix-bound nanovesicles derived from adipose-derived mesenchymal stem cells can be prepared stably. Attached Figure Description
[0031] Figure 1 The preparation process and characterization results of adipose-derived mesenchymal stem cell-derived decellularized extracellular matrix (ADSC-dECM) and matrix-bound nanovesicles (MBVs) are described; among which: Figure 1 Figure A in the middle is a schematic diagram of the separation process of culture supernatant-derived extracellular vesicles (SuEVs) and decellularized extracellular matrix-derived matrix-bound nanovesicles (MBVs); Figure 1 Figure B in the middle shows the characterization results of ADSC-dECM, including the retention of collagen I and fibronectin in the extracellular matrix after decellularization by immunofluorescence detection, as well as the evaluation results of the decellularization effect by bright-field microscopy, Hoechst 33342 staining and Actin-Tracker staining. Figure 1 Figure C shows the results of Western blot analysis of the expression levels of HSPA13, TSG101, and CD9 proteins in ADSC, ADSC-derived SuEVs, and ADSC-derived MBVs. Figure 1 The middle D figure shows the morphological structure of MBVs isolated from ADSC-dECM observed by transmission electron microscopy (TEM); Figure 1 Figure E shows the particle size distribution of MBVs separated from ADSC-dECM by nanoparticle tracking analysis (NTA). Figure 2 The results of proteomic characterization and functional protein screening of MBVs from ADSC sources; among which: Figure 2 Figure A in the middle is a Venn diagram of the identification of MBVs proteins by DIA proteomics analysis; Figure 2 Figure B in the middle shows the results of the Gene Ontology (GO) biological process enrichment analysis of MBVs proteins; Figure 2 Figure C shows the results of Western blot validation of the expression of some cell proliferation-related proteins obtained from proteomics screening; Figure 2 Figure D shows the results of Western blot analysis of EGFR protein expression levels in ADSC, ADSC-derived SuEVs, and ADSC-derived MBVs. Figure 2 The middle figure shows the results of EGFR localization on the surface of MBVs observed by immunogold labeling combined with TEM. Figure 3 The results of a study on the role of ADSC-derived MBVs in transferring EGFR and promoting the proliferation of limbal epithelial cells; among which: Figure 3 Figure A shows the results of Western blot analysis of EGFR protein expression levels in limbal epithelial cells (LECs) of the control group and the MBVs-treated group; Figure 3 Figure B is Figure 3 Statistical analysis results of grayscale values of EGFR protein expression in Figure A (n=3); Figure 3 Figure C shows the results of immunofluorescence detection of the localization of Flag-labeled proteins on the cell membrane of receptor LECs after co-culturing EGFR-Flag-labeled MBVs and LECs. Figure 3 Figure D shows the results of Western blot analysis of EGFR-Flag protein expression in LECs before and after treatment with EGFR-Flag-labeled MBVs; Figure 3 Figure E shows a schematic diagram of the experimental procedure for treating EGFR on the surface of MBVs with the EGFR neutralizing antibody Cetuximab; Figure 3 Figure F shows the results of Western blot analysis of changes in phosphorylated AKT (p-AKT) and AKT protein expression in LECs from different treatment groups; Figure 3 Figure G shows the results of Western blot analysis of changes in phosphorylated ERK (p-ERK) and ERK protein expression in LECs from different treatment groups; Figure 3 The H-plot shows the statistical analysis results of p-AKT / AKT expression levels (n=3); Figure 3 Figure I shows the statistical analysis results of p-ERK / ERK expression levels (n=3); Figure 3 The figure in Figure J shows the statistical analysis results of the proportion of EdU positive cells in each group (n=3); Figure 3 The K-plot shows the statistical analysis results of the proportion of Ki67 positive cells in each group (n=3); Figure 3 The middle figure shows the immunofluorescence results of the EdU incorporation experiment to detect the proliferation ability of LECs; Figure 3 The middle M figure shows the results of Ki67 immunofluorescence staining to detect the proliferation status of LECs; Figure 4 The results compare the therapeutic effects of MBVs eye drops and DMA films in a mouse model of corneal alkali burn; among which: Figure 4 Figure A shows the results of fluorescein sodium staining to detect corneal epithelial defects in different treatment groups; Figure 4 Figure B in the middle shows the statistical analysis results of the corneal epithelial defect score (n=6); Figure 5 The results of the evaluation of the therapeutic effect of MBVs eye drops on promoting corneal repair after alkali burn in mice; among which: Figure 5 Figure A shows the results of corneal transparency changes observed under a slit-lamp microscope in different treatment groups; Figure 5 Figure B in the middle shows the statistical analysis results of the corneal transparency score (n=6); Figure 5 Figure C shows the results of fluorescein sodium staining to detect corneal epithelial defects in different treatment groups; Figure 5 Figure D shows the statistical analysis results of the corneal epithelial defect score (n=6); Figure 5 Figure E shows the results of anterior segment optical coherence tomography (AS-OCT) detection of changes in central corneal thickness in different treatment groups; Figure 5 The F-figure shows the statistical analysis results of central corneal thickness (n=6); Figure 5 The middle G figure shows the H&E staining results of corneal tissue from different treatment groups on day 8 after injury; Figure 5 The H-plot in the middle shows the statistical analysis results of H&E staining for evaluating corneal epithelial thickness recovery (n=3); Figure 5 Figure I shows the results of Masson staining to detect the arrangement of corneal stromal collagen fibers in different treatment groups; Figure 5 Figure J shows the statistical analysis results of Masson staining evaluation of corneal stromal thickness recovery (n=3); Figure 6 The results of the long-term ocular surface safety evaluation of MBVs eye drops (n=3); among which: Figure 6 Figure A shows the H&E staining results of mouse corneal tissue after long-term administration of MBVs eye drops; Figure 6 Figure B shows the Masson staining results of mouse corneal tissue after long-term administration of MBVs eye drops; Figure 6 Figure C shows the H&E staining results of major organs (heart, liver, spleen, lung, and kidney) in mice after long-term administration of MBVs eye drops. Figure 7 This is a graph showing the flow cytometry results from Example 1; Figure 8 A schematic diagram illustrating the construction of the EGFR-Flag expression vector; Figure 9 Results of cell proliferation activity assay by CCK-8 assay after treating LECs with different particle concentrations of ADSC-MBVs for 24 h (n=4); Figure 10 To set up the isotype control antibody group, the immunofluorescence results of the EdU incorporation assay to detect the proliferation ability of LECs in each group and the statistical analysis results of the proportion of EdU positive cells were included. The groups were the control group (Blank), the ADSC-MBVs treatment group (MBV), the ADSC-MBVs treatment group pretreated with isotype control antibody (MBV+isotype IgG), and the ADSC-MBVs treatment group pretreated with Cetuximab (MBV+anti-EGFR) (n=3). Figure 11 The results of RT-qPCR detection of the relative expression level of EGFR mRNA in LECs after 6 h, 12 h and 24 h of ADSC-MBV treatment (n=3). Detailed Implementation
[0032] In this document, the range expressed as "from one value to another" is a concise way of representing a range to avoid listing all the values in that range in the specification. Therefore, the description of a particular range of values covers any value within that range as well as the smaller range of values defined by that value, just as if the arbitrary value and the smaller range of values were explicitly stated in the specification.
[0033] In this application, unless otherwise stated, the use of "or" means "and / or". In the case of multiple dependent claims, "or" is used only in alternatives to refer to more than one of the aforementioned independent or dependent claims.
[0034] The English abbreviations involved in this invention and their meanings are as follows: ADSC refers to adipose-derived mesenchymal stem cells; dECM refers to decellularized extracellular matrix; ADSC-dECM refers to decellularized extracellular matrix derived from adipose-derived mesenchymal stem cells; MBVs refers to matrix-bound nanovesicles; ADSC-MBVs refers to matrix-bound nanovesicles derived from adipose-derived mesenchymal stem cells; SuEVs refers to extracellular vesicles derived from culture supernatant; sIVs refers to intracellular nanovesicles; EGFR refers to epidermal growth factor receptor; LECs refers to limbal epithelial cells; EVs refers to extracellular vesicles; DMA refers to decellularized stromal membranes.
[0035] Adipose-derived mesenchymal stem cell-derived decellularized matrix (DMA) retains the active components of the extracellular matrix and has the ability to promote corneal repair, but when applied in the form of a membrane, it requires surgical transplantation. Intracellular nanovesicles (sIVs) obtained by ultrasonic cell disruption can be prepared into eye drops, but they are derived from cell disruption products and differ in origin and composition from matrix-bound nanovesicles (MBVs) that naturally exist in the extracellular matrix. Existing ophthalmic applications of MBVs are mainly based on tissue-derived decellularized matrix and do not involve corneal epithelial damage repair, nor have the functional molecules that play a role in them been clearly identified.
[0036] Based on this, the present invention uses the extracellular matrix secreted and deposited by adipose-derived mesenchymal stem cells (ADSC) during in vitro culture as the source carrier of MBVs. After decellularization, adipose-derived acellular extracellular matrix (ADSC-dECM) is obtained. Then, after enzymatic release and centrifugation, matrix-bound nanovesicles (ADSC-MBVs) derived from adipose-derived mesenchymal stem cells are obtained and used for corneal epithelial damage repair.
[0037] In this application, ADSC-MBVs are defined by their source (acellular extracellular matrix derived from adipose-derived mesenchymal stem cells) and preparation method (obtained through enzymatic decomposition and centrifugation), which distinguishes them from extracellular vesicles (SuEVs) derived from culture supernatant obtained directly from conditioned culture medium and intracellular nanovesicles (sIVs) obtained by ultrasonic disruption of cells.
[0038] Based on this, the present invention further confirmed through proteomics analysis and Western blot, immunogold electron microscopy, etc., that the ADSC-MBVs are enriched with epidermal growth factor receptor (EGFR) on their surface; and through EGFR-Flag tracing and EGFR neutralizing antibody blocking experiments, it was confirmed that the EGFR carried on the surface of the ADSC-MBVs can transfer and localize to the limbal epithelial cell membrane, activate the PI3K / AKT signaling pathway and MAPK / ERK signaling pathway of the limbal epithelial cells, thereby promoting the proliferation of corneal epithelial cells. That is, EGFR is the functional molecule for ADSC-MBVs to exert the corneal epithelial repair function.
[0039] Therefore, this invention provides an application of matrix-bound nanovesicles derived from adipose-derived mesenchymal stem cells in the preparation of drugs for corneal epithelial injury repair: using ADSC-dECM as the source carrier (distinct from tissue-derived dECM and DMA sheets) → obtaining ADSC-MBVs (distinct from cell-disrupted sIVs) through enzymatic decomposition → enriching EGFR on the surface of the ADSC-MBVs and thereby regulating corneal epithelial cell proliferation signals → preparing it as an eye drop formulation for corneal epithelial injury repair (achieving non-invasive local drug delivery).
[0040] Example 1
[0041] This embodiment is used to obtain adipose-derived mesenchymal stem cells required for constructing ADSC-dECM.
[0042] Adipose tissue was used as the cell source, obtained during liposuction or double eyelid surgery. The obtained adipose tissue was washed with PBS buffer containing 100 U / mL penicillin / streptomycin to remove blood and tissue debris. The washed adipose tissue was then minced and digested with collagenase A solution. In this embodiment, the concentration of collagenase A solution was 0.2% (2 mg / mL), and digestion was carried out at 37°C for 2.5 h. It should be noted that in alternative embodiments, the concentration of collagenase A solution may also be 0.1%–0.2% (1–2 mg / mL), and the digestion time may be 2–3 h.
[0043] After digestion, the digestive fluid is centrifuged and the precipitate is collected to obtain primary adipose-derived mesenchymal stem cells. In this embodiment, the centrifugation conditions are 1500 rpm for 12 min. It should be noted that in alternative embodiments, centrifugation at 1000-1500 rpm for 8-12 min is also possible.
[0044] The obtained adipose-derived mesenchymal stem cells (ADSCs) were resuspended in culture medium and seeded into culture dishes, then cultured at 37°C and 5% CO2. The culture medium included α-MEM medium, 10% fetal bovine serum, and 100 U / mL penicillin / streptomycin. The culture medium was changed every 2 days during the culture process. When the cell confluence reached 80%–90%, the cells were passaged and cryopreserved. The obtained ADSCs were then expanded through culture and used for the subsequent preparation of ADSC-dECM.
[0045] To verify the mesenchymal stem cell phenotype of the obtained cells, fourth-generation ADSCs were harvested. When the cell density approached 90%, the cells were digested with trypsin, repeatedly pipetted, neutralized with serum-containing culture medium, centrifuged at 800 rpm for 4 min, the supernatant was discarded, and the cells were resuspended in PBS and centrifuged at 800 rpm for 4 min. This washing process was repeated three times, and the cell concentration was adjusted to 1×10⁻⁶ cells / min. 6 / mL. CD29, CD73, CD105, CD14, CD31, CD34, CD45, and corresponding isotype control antibodies were added according to the antibody instructions for flow cytometry staining. The cells were incubated in the dark for 30 min, gently washed three times with PBS, resuspended, and then analyzed by flow cytometry. Results are as follows: Figure 7 As shown, the obtained cells highly expressed mesenchymal matrix / stem cell-related surface markers CD29, CD73, and CD105, while the expression levels of CD14, CD31, CD34, and CD45 were low or close to the detection limit, exhibiting a typical mesenchymal matrix / stem cell phenotype, indicating that the obtained cells conform to the phenotypic characteristics of ADSCs.
[0046] Example 2
[0047] This embodiment provides the preparation of adipose-derived acellular extracellular matrix (ADSC-dECM) derived from adipose-derived mesenchymal stem cells.
[0048] After obtaining and expanding adipose-derived mesenchymal stem cells using the method described in Example 1, the fourth-generation adipose-derived mesenchymal stem cells were seeded into a culture plate for extracellular matrix deposition culture.
[0049] Specifically, the steps include: dividing adipose-derived mesenchymal stem cells into groups of 5 × 10⁻⁶. 5 Adipose-derived mesenchymal stem cells (ADMSCs) were seeded at a density of 100 cells / well in 6-well culture plates. The culture medium included α-MEM medium, 10% exosome-free fetal bovine serum (Catalog No.: FBSNE-01061), and 100 U / mL penicillin / streptomycin. The culture medium was changed on day 1 after seeding, and then every 2 days thereafter, for a total of 14 days, to allow the AMSCs to secrete and deposit the extracellular matrix, forming the extracellular matrix structure.
[0050] After culture, the cell layer underwent decellularization. Specifically, it was treated with a combination of 0.5% Triton X-100 and 20 mM ammonium hydroxide for 5 min to remove cellular components while preserving the extracellular matrix structure and its embedded bioactive components. After decellularization, the cells were washed twice with Hanks balanced salt solution and once with ultrapure water to remove residual decellularization reagents and cell debris, yielding adipose-derived mesenchymal stem cell-derived decellularized extracellular matrix (ADSC-dECM).
[0051] Adipose-derived mesenchymal stem cell-derived decellularized extracellular matrix (MBVs) was used as the extraction source. Its role is to preserve the extracellular microenvironment formed during the in vitro culture of adipose-derived mesenchymal stem cells, providing a source carrier for subsequent acquisition of matrix-bound nanovesicles. For example... Figure 1 As shown in Figure B, the obtained ADSC-dECM retained extracellular matrix components such as collagen I and fibronectin through immunofluorescence detection. No obvious cell nuclei or cytoskeleton residues were observed by bright field observation, Hoechst 33342 staining and Actin-Tracker staining, indicating that effectively decellularized ADSC-dECM was obtained.
[0052] In another embodiment, in addition to using Triton X-100 and ammonium hydroxide in combination, the decellularization treatment can also use sodium dodecyl sulfate (SDS), deoxycholate, or other methods that can remove cellular components while retaining the extracellular matrix structure; the deposition culture of the extracellular matrix is not limited to the above two-dimensional culture system, but can also use a three-dimensional culture system.
[0053] Example 3
[0054] This embodiment provides the preparation and characterization of ADSC-derived matrix-bound nanovesicles (ADSC-MBVs).
[0055] The preparation of ADSC-derived matrix-bound nanovesicles (ADSC-MBVs) includes the following steps: After taking the ADSC-dECM prepared in Example 2, it was subjected to enzymatic hydrolysis to release matrix-bound nanovesicles (MBVs) embedded in the extracellular matrix.
[0056] Specifically, ADSC-dECM was added to a digestion system containing Liberase TL for enzymatic digestion, wherein the concentration of Liberase TL was 0.01 mg / mL, and the digestion solution included 50 mM Tris buffer, 5 mM CaCl2 and 150 mM NaCl, with a buffer pH of 7.8; the above system was placed at 37°C for 1 h for digestion to release MBVs embedded in the decellularized matrix into the solution.
[0057] Meanwhile, to compare the characteristics of extracellular vesicles from different sources, culture supernatant produced during the culture of adipose-derived mesenchymal stem cells was collected to isolate extracellular vesicles (SuEVs) from the culture supernatant.
[0058] Subsequently, samples containing MBVs or SuEVs were subjected to differential centrifugation to remove large particulate impurities and cell debris. The differential centrifugation was performed sequentially: 500×g for 10 min; 2000×g for 10 min; and 10000×g for 30 min. The supernatant was collected, filtered through a 0.22 μm filter, and then further enriched with nanovesicles using ultracentrifugation at 100000×g, 4℃ for 90 min. The resulting vesicle precipitate was washed with PBS buffer and resuspended to obtain ADSC-derived MBVs and SuEVs, which were stored at -80℃ for later use.
[0059] This invention obtains MBVs by enzymatically releasing ADSC-dECM. The preparation method is different from obtaining intracellular nanovesicles (sIVs) by ultrasonically disrupting cells. The obtained MBVs are derived from the extracellular matrix microenvironment and retain the bioactive components stored in the extracellular matrix.
[0060] To verify that the product obtained by the above method has the characteristics of matrix-bound nanovesicles, this embodiment further detects the morphology, particle size, and vesicle marker proteins of ADSC-MBVs. Figure 1 As shown in Figure D, transmission electron microscopy (TEM) reveals that ADSC-MBVs exhibit a nanovesicle morphology. Figure 1 As shown in Figure E, nanoparticle tracking analysis (NTA) revealed that the particle size distribution of ADSC-MBVs conforms to the characteristics of nanoscale vesicles, with a particle size distribution range of approximately 20–400 nm and a peak particle size distribution of approximately 118 nm.
[0061] To further illustrate the typical yield and batch repeatability of the ADSC-MBVs preparation method described in this invention, three independent batches of ADSC-MBVs were prepared according to the above method. Statistical analysis was performed on the dry weight of ADSC-dECM input in each batch, the particle concentration of the obtained ADSC-MBVs, the total particle yield, the median particle size, and the particle yield normalized to dECM per unit mass. The results are shown in Table 1.
[0062] Table 1. Yield and particle size characteristics of different batches of ADSC-MBVs Batch 1 Batch 2 Batch 3 Mean ± SD dECM dry weight (mg) 64.8 43.2 75.6 61.2 ± 16.5 MBV particle concentration (× 10¹¹ particles / mL) 2.9 1.5 3.8 2.73 ± 1.16 MBV (Total Particle Volume) (×10¹⁰ particles / batch) 5.8 3.0 7.6 5.47 ± 2.32 Median particle size (nm) 128.3 128.0 126.1 127.47 ± 1.19 Particle yield per unit mass of dECM (× 10⁸ particles / mg dECM) 8.95 6.94 10.05 8.65 ± 1.58 The results showed that the dry weights of dECM used in the three independent batches were 64.8 mg, 43.2 mg, and 75.6 mg, respectively, with an average of 61.2 ± 16.5 mg; the resulting ADSC-MBVs particle concentrations were 2.9 × 10⁻⁶. 11 1.5×10 11 and 3.8×10 11The average number of particles / mL was (2.73 ± 1.16) × 10⁻⁶. 11 particles / mL; the total particle yield for each batch was 5.8 × 10⁻⁶. 10 3.0×10 10 and 7.6×10 10 The average number of particles per batch is (5.47 ± 2.32) × 10⁻⁶. 10 Particles / batch. After normalization to dECM dry weight, the ADSC-MBVs particle yield per unit mass of dECM is 8.95 × 10⁻⁶. 8 6.94×10 8 and 1.005×10 9 The average number of particles / mg dECM was (8.65±1.58)×10⁻⁶. 8 The results show that, despite variations in dECM input amounts across different batches, the yield of ADSC-MBVs normalized to per unit mass of dECM remains relatively concentrated. Furthermore, the median particle sizes of the ADSC-MBVs obtained from the three independent batches were 128.3 nm, 128.0 nm, and 126.1 nm, with an average of 127.47 ± 1.19 nm, indicating a relatively consistent particle size characteristic across different batches. These results demonstrate that the ADSC-MBVs preparation method described in this invention exhibits good batch reproducibility and can stably prepare ADSC-MBVs.
[0063] In this application, ADSC-MBVs are defined primarily based on their origin and preparation method. Specifically, they are obtained from decellularized extracellular matrix (ADSC-dECM), derived from the extracellular matrix deposited during in vitro culture of adipose-derived mesenchymal stem cells, through enzymatic release and centrifugation, rather than directly from the conditioned culture medium of adipose-derived mesenchymal stem cells. The aforementioned transmission electron microscopy (TEM), nanoparticle tracking analysis (NTA), and Western blot results indicate that the obtained product possesses the morphology, particle size distribution, and extracellular vesicle-related protein characteristics of nanoscale vesicles.
[0064] As shown in Figure 1C, Western blot was used to detect vesicle-related proteins in ADSC, ADSC-SuEVs, and ADSC-MBVs. CD9 and TSG101 are extracellular vesicle (EV)-related proteins, and HSPA13 was used as a reference protein. The results showed that ADSC-MBVs expressed CD9 and TSG101, but no obvious HSPA13 expression was detected, indicating that the obtained products have the characteristics of extracellular vesicle-related proteins. It should be noted that the positive results for CD9 and TSG101 in this application are only used to support the extracellular vesicle nature of the obtained product, and are not used to characterize its specificity relative to vesicles from other sources. It is known in the art that the protein composition and surface markers of matrix-bound nanovesicles have obvious source specificity and tissue specificity. At present, there is no single protein marker that can be used as an absolute specific identification indicator for all matrix-bound nanovesicles. Therefore, this application does not use CD9, TSG101 or other single proteins as necessary conditions for determining ADSC-MBVs, but uses their source and preparation method as the basis for definition.
[0065] In this application, MBVs are obtained by releasing and separating ADSC-dECM from the matrix after enzymatic digestion, while SuEVs are obtained by separating them from the supernatant of adipose-derived mesenchymal stem cell culture; the two have different origins. Figure 1 As shown in Figure C, there are differences in the expression of vesicle-related proteins among ADSC, ADSC-SuEVs, and ADSC-MBVs, indicating that MBVs obtained by enzymatic hydrolysis and release from the extracellular matrix are different in composition from SuEVs derived from culture supernatant, confirming that ADSC-MBVs are matrix-bound nanovesicles derived from the extracellular matrix microenvironment.
[0066] In another embodiment, in addition to Liberase TL, the enzyme decomposition and release can also use enzymes such as collagenase and proteinase K that can degrade the extracellular matrix and release vesicles; in addition to differential centrifugation combined with ultra-high speed centrifugation, the vesicle purification can also be carried out by density gradient centrifugation, filtration purification or size exclusion chromatography.
[0067] Example 4
[0068] To clarify the functional molecular composition carried by ADSC-MBVs, this embodiment uses data-independent acquisition (DIA) proteomics technology to analyze the ADSC-MBVs proteome.
[0069] Specifically, protein extraction was performed on the obtained ADSC-MBVs. Total protein was extracted using an ultrasonic disruption method with PMSF, and protein quantification was performed using the BCA method. 50 μg of total protein was taken from each biological replicate and enzymatically digested using the SP3 (Single-PotSolid-Phase-enhanced Sample Preparation) method. Specifically, the protein samples were reduced with 10 mM dithiothreitol (DTT), alkylated with 20 mM iodoacetamide (IAM), and then trypsin was added. Enzymatic digestion was carried out overnight at 37°C to obtain peptide samples. Three biological replicates were set up for each group. The peptides obtained from enzymatic digestion were desalted using a C18 Stage-Tip and then analyzed for proteomics using liquid chromatography-mass spectrometry.
[0070] During liquid chromatography (LC) separation, peptides were first loaded onto a trap column (75 μm × 2 cm, NanoViper C18, 3 μm), followed by separation using an analytical column (150 μm inner diameter × 170 mm, Reprosil-Pur 120 C18-AQ, 1.9 μm, 100 Å) with a gradient elution of 120 min at a flow rate of 300 nL / min. Mass spectrometry (MS) was performed using a LC-MS system (Vanquish Neo LC system and OrbitrapExploris 480 MS spectrometer, Thermo Fisher Scientific), and data were acquired in data-independent acquisition (DIA) mode. The full scan range was 400–1100 m / z, the first-order mass spectrometry resolution was set to 120,000, and the second-order mass spectrometry resolution was set to 30,000, with 40 fixed isolation windows used for data acquisition.
[0071] The raw mass spectrometry data were analyzed using DIA-NN software. Protein identification was performed based on the UniProt human protein database. By controlling the false discovery rate (FDR) of proteins and precursor ions to ≤1%, the protein composition information of ADSC-MBVs was obtained. Further functional enrichment analysis of the identified proteins was performed using the GO, KEGG, and Reactome databases to analyze the protein composition and potential biological functions of ADSC-MBVs.
[0072] like Figure 2As shown in Figure A, DIA proteomics analysis identified the protein composition of ADSC-MBVs, and repeatability was evaluated by comparing protein identification results between different samples. Figure 2 As shown in Figure B, GO functional enrichment analysis revealed that the proteins carried by ADSC-MBVs are involved in biological processes such as cell proliferation regulation. Figure 2 As shown in Figure C, screening and Western blot validation of proteins involved in cell proliferation regulation revealed that ADSC-MBVs are enriched in the expression of a variety of proteins related to cell function regulation.
[0073] like Figure 2 As shown in Figure D, Western blot analysis of EGFR protein expression in ADSCs, SuEVs, and ADSC-MBVs revealed that EGFR was enriched in ADSC-MBVs. Figure 2 As shown in Figure E, immunogold labeling combined with TEM observation revealed that EGFR was located on the surface of ADSC-MBVs.
[0074] The above results indicate that ADSC-MBVs are enriched with EGFR on their surface, providing a molecular basis for further verification of their role in promoting corneal epithelial cell proliferation.
[0075] Example 5
[0076] This embodiment provides an ADSC-MBVs eye drop formulation, the preparation of which includes the following steps: The ADSC-MBVs obtained and purified in Example 3 were resuspended in sterile PBS buffer to obtain an ADSC-MBVs eye drop formulation. The particle concentration was 1×10⁻⁶. 11 ~5×10 11 The particle / mL ratio is preferably 2.5 × 10⁻⁶. 11 particles / mL. The ADSC-MBVs eye drops are administered topically to the ocular surface, with each dose being 5 μL, twice daily.
[0077] The ADSC-MBVs eye drops formulation can act directly on the corneal surface, allowing MBVs to come into contact with corneal epithelial cells in the damaged area. Compared to adipose-derived mesenchymal stem cell-derived decellularized matrix membranes, which require surgical application to the ocular surface, this invention prepares components from the decellularized matrix into nanovesicle eye drops, achieving non-invasive local drug delivery to the ocular surface.
[0078] In another embodiment, the excipients of the formulation are not limited to PBS, but may also be ophthalmologically acceptable carrier materials such as ophthalmic buffer systems, hyaluronic acid, chitosan or thermosensitive hydrogels, to prepare an ophthalmic eye drop formulation, ophthalmic gel or ophthalmic sustained-release formulation containing hyaluronic acid; the administration method is not limited to eye drops, but may also be a local ophthalmic administration method such as subconjunctival injection or corneal surface coverage.
[0079] Example 6
[0080] The limbal epithelial cells (LECs) used in this embodiment were isolated and cultured as follows: Human limbal tissue was obtained after approval by the medical ethics committee [see Note 1], and the tissue originated from the donor corneal ring remaining after central corneal transplantation surgery. Primary culture was used to isolate LECs: The limbal tissue was treated with 2.5 mg / mL Dispase II at 4°C for 8 h. After separating the epithelial cell layer, it was digested with TrypLE at 37°C for 8 min to obtain single limbal epithelial cells. The obtained cells were resuspended in DMEM / F12 medium containing 0.1% Y27632, 1% B27, 10 ng / mL EGF, and 1% penicillin-streptomycin. The medium was changed every 2 days. When the confluence reached 80%–90%, the cells were passaged using TrypLE. Primary human LECs from passages 2–4 were used for subsequent experiments.
[0081] This embodiment evaluates the effects of ADSC-MBVs on limbal epithelial cells (LECs) and verifies its mechanism. The results are as follows: Figure 3 As shown.
[0082] To determine the optimal concentration of ADSC-MBVs for subsequent cell experiments, the CCK-8 assay was first used to screen the effective concentration of ADSC-MBVs. Specifically, LECs were prepared at a concentration of 6 × 10⁻⁶. 3 The cells were seeded at a density of 10 cells / well in 96-well plates and treated with different concentrations of ADSC-MBVs for 24 h. Cell Counting Kit-8 (CCK-8, catalog number: ES7011) reagent was then added, and the plates were incubated at 37°C for another 4 h. The absorbance (n=4) was measured at 450 nm using a Bio-Tek microplate reader. Results are as follows: Figure 9 As shown, when the concentration of ADSC-MBVs particles is 5 × 10⁻⁶, 3 The most significant promoting effect on LEC proliferation activity was observed at a concentration of particles / mL; therefore, the concentration of ADSC-MBVs was 5 × 10⁻⁶ in subsequent cell experiments. 3 particles / mL.
[0083] ADSC-MBVs were co-cultured with LECs (final concentration of ADSC-MBVs was 5 × 10⁻⁶). 9 particles / mL, treated for 6 hours), such as Figure 3 As shown in Figures A and B, Western blot analysis revealed enhanced EGFR protein signaling in LECs treated with MBVs. To further verify whether this EGFR signal originated from exogenous EGFR carried by ADSC-MBVs, rather than changes in EGFR expression levels within the LECs themselves, and to further confirm the transfer of EGFR from the surface of ADSC-MBVs to recipient cells, EGFR-Flag-labeled ADSC-MBVs were used for tracing experiments.
[0084] The EGFR-Flag-labeled ADSC-MBVs were prepared as follows: the EGFR target gene was constructed into the lentiviral expression vector PGMLV-CMV-MCS-3×Flag-T2A-Puro (brand / product number: Genomeditech / PGMLV-5165) using a seamless cloning method and verified by sequencing; the obtained expression plasmid was co-transfected with GM easy™ LentiviralMix (Genomeditech / GMLCP-10) into HEK-293T cells for lentiviral packaging, and the viral supernatant was collected after 48 h of culture. The supernatant was filtered through a 0.45 μm filter membrane and concentrated by ultrafiltration. The lentiviral titer was determined by RT-qPCR targeting the WPRE sequence. P2-P3 generation ADSCs were transduced with the above-mentioned EGFR-Flag lentivirus at an MOI of 80, with 5 μg / mL polybrene added. After 72 h of transduction, EGFR-Flag expression was confirmed by immunofluorescence. The ADSCs with confirmed expression were further prepared into ADSC-MBVs according to the method described in this application, thus obtaining EGFR-Flag labeled ADSC-MBVs.
[0085] A schematic diagram of the EGFR-Flag expression vector construction is shown below. Figure 8 As shown.
[0086] like Figure 3 As shown in Figure C, immunofluorescence assay revealed that the Flag-labeled protein was localized on the cell membrane of receptor LECs; Figure 3As shown in Figure D, Western blot analysis revealed the presence of EGFR-Flag protein in treated LECs. Since EGFR-Flag is an exogenous marker protein pre-expressed in donor ADSCs and carried with the ADSC-MBVs prepared from them, and the recipient LECs themselves do not contain this Flag tag, the EGFR-Flag detected in treated LECs originates from EGFR-Flag-labeled ADSC-MBVs, rather than a signal generated by changes in EGFR expression levels within the LECs themselves. These results indicate that EGFR carried on the surface of ADSC-MBVs can transfer and localize to the LEC cell membrane.
[0087] To further rule out the possibility of recipient cells upregulating EGFR expression themselves, RT-qPCR was used to detect the mRNA level of EGFR in LECs treated with ADSC-MBVs. The results are as follows: Figure 11 As shown, after 6 h, 12 h and 24 h of ADSC-MBVs treatment, the relative expression level of EGFR mRNA in LECs was not significantly upregulated compared with the control group. This indicates that the increase in EGFR protein level in LECs after ADSC-MBVs treatment mainly comes from the exogenous EGFR carried by ADSC-MBVs and transferred to the recipient cell membrane, rather than the upregulation of the EGFR gene transcription level in LECs themselves.
[0088] To verify the activation of the signaling pathway and the role of EGFR, the EGFR-neutralizing antibody Cetuximab was used to treat the EGFR on the surface of MBVs (procedure as follows). Figure 3 As shown in Figure E, the expression changes of signaling pathway-related proteins in LECs from different treatment groups are compared.
[0089] Specifically, 20 μg of ADSC-MBVs were incubated with Cetuximab (MCE, catalog number: HY-P9905) at a final concentration of 5 μg / mL at 4°C for 2 h. Unbound free antibody was then removed by ultracentrifugation (150,000 × g, 2 h). The resulting treated ADSC-MBVs were used for subsequent cell experiments. It should be noted that the untreated ADSC-MBVs group (MBV group) underwent the same 4°C incubation for 2 h and 150,000 × g ultracentrifugation for 2 h steps, but without the addition of antibody, to ensure that the amount of ADSC-MBVs added was consistent across groups and that the treatment conditions were comparable.
[0090] like Figure 3As shown in Figures F to I, ADSC-MBVs treatment can increase the levels of p-AKT / AKT and p-ERK / ERK in LECs, that is, activate the PI3K / AKT signaling pathway and the MAPK / ERK signaling pathway; while after blocking the EGFR on the MBVs surface with Cetuximab, the activation of the above signaling pathways is significantly weakened.
[0091] Furthermore, to investigate the effect of ADSC-MBVs on the proliferation of LECs and to verify the role of EGFR, primary human LECs were divided into a control group (Blank), an ADSC-MBVs treatment group (MBV), and an ADSC-MBVs pretreated with Cetuximab group (MBV+anti-EGFR): the Blank group received no ADSC-MBVs treatment; the MBV group received ADSC-MBVs treatment; and the MBV+anti-EGFR group received ADSC-MBVs pretreated with Cetuximab. All groups were cultured under the same conditions, and the proliferation level of LECs was detected by EdU incorporation assay and Ki67 immunofluorescence staining.
[0092] like Figure 3 As shown in Figures J-M, the EdU incorporation assay and Ki67 immunofluorescence staining results indicate that ADSC-MBVs treatment can increase the proportion of EdU-positive cells and Ki67-positive cells in LECs, i.e., promote LECs proliferation; this proliferation-promoting effect is inhibited after blocking EGFR on the surface of MBVs with Cetuximab.
[0093] To eliminate the influence of non-specific antibody binding on the above results, an isotype control antibody group was further set up for verification. Specifically, 20 μg of ADSC-MBVs were incubated at 4℃ for 2 h with either Cetuximab (MCE, catalog number: HY-P9905) or isotype control antibody (Human IgG1 kappa, Isotype Control, MCE, catalog number: HY-P99001) at a final concentration of 5 μg / mL, followed by ultracentrifugation (150000×g, 2 h) to remove unbound free antibodies. The MBV group underwent the same incubation and ultracentrifugation steps, but without the addition of antibodies. The ADSC-MBVs treated in each group were co-cultured with LECs, and the proliferation level of LECs was detected by EdU incorporation assay. The results are as follows: Figure 10As shown, compared with the control group (Blank), the proportion of EdU-positive cells in LECs was increased in the MBV group; the proliferative effect of ADSC-MBVs pretreated with isotype control antibody (MBV+isotype IgG group) on LECs was not significantly different from that in the MBV group; however, the proliferative effect was inhibited after blocking EGFR on the surface of ADSC-MBVs with Cetuximab (MBV+anti-EGFR group). These results indicate that the inhibitory effect produced by Cetuximab is due to its specific blocking of EGFR on the surface of ADSC-MBVs, rather than due to non-specific binding of the antibody or vesicle loss caused by ultracentrifugation.
[0094] The above results indicate that EGFR carried on the surface of ADSC-MBVs can be transferred and localized to the limbal epithelial cell membrane, and activate the PI3K / AKT and MAPK / ERK signaling pathways of limbal epithelial cells, thereby promoting corneal epithelial cell proliferation; EGFR is the functional molecule by which ADSC-MBVs exert the above effects.
[0095] Example 7
[0096] This embodiment evaluated the in vivo performance and safety of ADSC-MBVs eye drops in promoting corneal damage repair. (1) Evaluation of in vivo corneal damage repair effect A mouse model of corneal alkali burn was established. Treatment groups included a PBS group, an ADSC-MBVs eye drop preparation group, and a Bepanthen eye drop group. The treatment protocol was as follows: Figure 5 As shown in A; a separate DMA sheet group was set up for comparison ( Figure 4 ).
[0097] Specifically, 6-8 week old female BALB / c mice were selected as experimental animals, with 6 mice per group for evaluating the in vivo corneal injury repair effect. After general and local anesthesia, a 2 mm diameter circular Whatman III filter paper disc, soaked in 1 N NaOH solution, was placed on the central corneal surface of the mouse's right eye for 30 seconds to induce corneal alkali burn. Immediately after removing the filter paper, the cornea and ocular surface were rinsed with sterile PBS for 1 min. After successful modeling, the mice were randomly assigned to groups. All treatment groups received ocular drops, 5 μL each time, twice daily for 7 consecutive days: the PBS group received an equal volume of PBS, the ADSC-MBVs ocular drop group received ADSC-MBVs ocular drops, and the Bepanthen ocular drop group received Bepanthen ocular drops. The DMA sheet group received topical lyophilized human fibrin adhesive applied to the mouse ocular surface, and the DMA sheet was uniformly fixed to the ocular surface, ensuring full contact between the cornea and ocular surface before subsequent observation and evaluation.
[0098] like Figure 4 Figures A-B and Figure 5 As shown in Figures C-D, the results of sodium fluorescein staining and corneal epithelial defect scoring indicate that, compared with the PBS group, the ADSC-MBVs eye drop group showed a smaller corneal epithelial defect area and faster epithelial healing. Its effect in promoting corneal epithelial defect repair was not inferior to that of Bepanthen eye drops and DMA films. Figure 5 As shown in Figures A and B, slit-lamp microscopy and corneal transparency scoring revealed that the ADSC-MBVs eye drops group exhibited reduced corneal opacity and restored transparency. Figure 5 As shown in Figures E-F, AS-OCT testing and central corneal thickness statistics revealed that the ADSC-MBVs eye drop group exhibited reduced central corneal thickness and decreased corneal edema. Figure 5 As shown in Figures G-H, H&E staining and corneal epithelial thickness statistics indicate that the ADSC-MBVs eye drop formulation formed a relatively complete multilayered epithelial structure. Figure 5 As shown in Figures I-J, Masson staining and corneal stromal thickness statistics show that the corneal stromal collagen fibers in the ADSC-MBVs eye drop formulation group are arranged more regularly.
[0099] The above results indicate that ADSC-MBVs eye drops can promote the repair of corneal epithelial defects and the restoration of corneal tissue structure after corneal alkali burn in mice.
[0100] (2) Safety evaluation Histological examination was performed on mice after long-term administration of ADSC-MBVs eye drops. The number of animals in each group was 3 in this safety evaluation.
[0101] Specifically, mice were given ADSC-MBVs eye drops twice daily, 5 μL each time, for 30 consecutive days, followed by histological examination.
[0102] The results are as follows Figure 6 As shown. Figure 6 As shown in Figures A and B, H&E staining and Masson staining revealed no significant abnormalities in the corneal tissue structure after long-term drug administration, and no abnormal collagen deposition was observed. Figure 6 As shown in Figure C, H&E staining of major organs such as the heart, liver, spleen, lungs, and kidneys showed no obvious tissue damage. These results indicate that ADSC-MBVs eye drops have good safety for ocular surface application.
[0103] All experimental data in this application are expressed as mean ± standard deviation (mean ± SD). Statistical analysis was performed using GraphPad Prism 10.0 software (GraphPad Software, USA). Unless otherwise specified, each experiment was performed at least three times independently, and the specific sample size (n) is indicated in the corresponding figure caption according to the nature of each experiment. Student's t-test was used for comparisons between two groups; comparisons between multiple groups were performed using one-way ANOVA combined with Tukey's post-hoc multiple comparison test, or two-way ANOVA combined with Bonferroni's post-hoc multiple comparison test, depending on the experimental design. A p-value < 0.05 was considered statistically significant. * indicates p < 0.05, ** indicates p < 0.01, *** indicates p < 0.001, and **** indicates p < 0.0001, used to indicate statistically significant differences between groups. The above description is merely a specific embodiment of the present invention, but the scope of protection of the present invention is not limited thereto. Any equivalent substitutions or modifications made by those skilled in the art within the technical scope disclosed in the present invention, based on the technical solution and concept of the present invention, should be covered within the scope of protection of the present invention.
[0104] Under the guidance of the present invention and the above embodiments, those skilled in the art will readily foresee that all the raw materials or their equivalents, processing methods or their equivalents listed or exemplified in the present invention can achieve the present invention, and that the upper and lower limits and range values of the parameters of each raw material and processing method can also achieve the present invention. Examples are not listed one by one here.
Claims
1. The application of a matrix-bound nanovesicle derived from adipose-derived mesenchymal stem cells in the preparation of a drug for corneal epithelial injury repair, characterized in that, The matrix-bound nanovesicles are derived from the decellularized extracellular matrix formed by the in vitro culture and deposition of adipose-derived mesenchymal stem cells and obtained through decellularization. They are obtained by enzymatic decomposition and centrifugation, and the surface of the matrix-bound nanovesicles carries epidermal growth factor receptors.
2. The application according to claim 1, characterized in that, The matrix-bound nanovesicles were prepared through the following steps: (1) Culture adipose-derived mesenchymal stem cells to secrete and deposit them to form extracellular matrix; (2) The extracellular matrix obtained in step (1) is decellularized to obtain adipose-derived extracellular matrix from adipose-derived mesenchymal stem cells; (3) The decellularized extracellular matrix obtained in step (2) is subjected to enzymatic hydrolysis to release matrix-bound nanovesicles, which are then collected by differential centrifugation and ultra-high speed centrifugation to obtain the matrix-bound nanovesicles derived from adipose-derived mesenchymal stem cells.
3. The application according to claim 1, characterized in that, The epidermal growth factor receptor carried by the matrix-bound nanovesicles can be transferred and localized to the limbal epithelial cell membrane, and activate the PI3K / AKT signaling pathway and MAPK / ERK signaling pathway of the limbal epithelial cells.
4. The application according to claim 1, characterized in that, The corneal epithelial damage mentioned refers to corneal epithelial damage caused by corneal alkali burn.
5. The application according to claim 1 or 2, characterized in that, The drug is an eye drop formulation, wherein the concentration of matrix-bound nanovesicles in the eye drop formulation is 1×10⁻⁶. 11 ~5×10 11 particles / mL.
6. The application according to claim 2, characterized in that, The adipose-derived mesenchymal stem cells mentioned in step (1) are derived from adipose tissue obtained by liposuction or double eyelid surgery. The culture medium used for the extracellular matrix deposition culture includes α-MEM medium, exosome-free fetal bovine serum, and penicillin / streptomycin.
7. The application according to claim 2 or 6, characterized in that, In step (1), fourth-generation adipose-derived mesenchymal stem cells were used for extracellular matrix deposition culture, and the deposition culture time was 14 days.
8. The application according to claim 2, characterized in that, The decellularization process described in step (2) involves treating with 0.5% Triton X-100 and 20 mM ammonium hydroxide for 5 min, followed by washing with Hanks balanced salt solution and ultrapure water.
9. The application according to claim 2, characterized in that, The enzymatic digestion in step (3) is performed using Liberase TL, with a Liberase TL concentration of 0.01 mg / mL. The digestion solution includes 50 mM Tris buffer, 5 mM CaCl2 and 150 mM NaCl, with a buffer pH of 7.
8. Digestion is carried out at 37°C for 1 h.
10. The application according to claim 2, characterized in that, In step (3), the differential centrifugation is performed sequentially as follows: centrifugation at 500×g for 10 min, centrifugation at 2000×g for 10 min, and centrifugation at 10000×g for 30 min. The supernatant is collected and filtered through a 0.22 μm filter membrane. The ultra-high speed centrifugation is performed as follows: centrifugation at 100000×g and 4℃ for 90 min.
11. The application according to any one of claims 1-10, characterized in that, The matrix is bound to nanovesicles that express CD9 and TSG101, but not HSPA13.
12. A pharmaceutical composition for repairing corneal epithelial damage, characterized in that, The pharmaceutical composition comprises matrix-bound nanovesicles derived from adipose-derived mesenchymal stem cells and an ophthalmologically acceptable carrier, wherein the matrix-bound nanovesicles derived from adipose-derived mesenchymal stem cells are derived from decellularized extracellular matrix formed by in vitro culture and deposition of adipose-derived mesenchymal stem cells and obtained by decellularization, enzymatic release and centrifugation, and the surface of the matrix-bound nanovesicles carries epidermal growth factor receptors.
13. The pharmaceutical composition according to claim 12, characterized in that, The pharmaceutical composition is an ophthalmic preparation.
14. The pharmaceutical composition according to claim 13, characterized in that, The ophthalmic preparation is an eye drop, ophthalmic gel, or ophthalmic sustained-release preparation.
Citation Information
Patent Citations
Ocular Applications of Matrix-Bound Vesicles (MBV)
CN110582286B
Biological material for corneal injury repair, and preparation method and applications thereof
CN113425909A
Application of intracellular nano-vesicles derived from adult stem cells in treatment of ophthalmic diseases
CN118178472A
